HealthEquity Reports First Quarter Ended April 30, 2026 Financial Results; Raises Guidance

Increases Repurchase Program by $1.0 Billion

Highlights of the
first
quarter include:

  • Net income increased 29% to $69.4 million, and net income margin increased to 20% from 16% last year.
  • Adjusted EBITDA increased 17% to $164.5 million, and Adjusted EBITDA margin increased to 46% from 42% last year.
  • Revenue increased 7% to $354.6 million.
  • Net income per diluted share rose 34% to $0.82 from $0.61 one year ago, and non-GAAP net income per diluted share increased 28% to $1.24.
  • Total HSA Assets grew 19% to $37.1 billion.
  • Returned $123.0 million to shareholders through stock repurchases.

DRAPER, Utah, May 28, 2026 (GLOBE NEWSWIRE) — HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent health savings account (“HSA”) custodian by account volume and a leader in consumer-directed benefits (“CDBs”), today announced financial results for its first quarter ended April 30, 2026.

“HealthEquity delivered strong first‑quarter results, with Adjusted EBITDA margin expanding to 46% and a raised fiscal 2027 outlook,” said Scott Cutler, President and CEO of HealthEquity. “These results demonstrate that our flywheel is compounding through account and asset growth, deeper member engagement, technology‑enabled efficiency, and increasing operating leverage. As healthcare affordability structurally shifts more responsibility to consumers, demand for trusted healthcare financial solutions continues to expand. Our authorization of an additional $1 billion under our share repurchase program reflects our confidence in the durability and long-term cash-generating power of our model.”

HealthEquity’s growth model is built on two reinforcing drivers: growth in member accounts and their HSA Assets over time and expansion in the lifetime value of each member relationship as engagement and activity increase. As accounts mature, these dynamics can compound, supporting durable growth and margin expansion while reducing reliance on short-term employment trends and new account additions in any single period.

First
quarter financial results

Revenue for the first quarter ended April 30, 2026 was $354.6 million, an increase of 7% compared to $330.8 million for the first quarter ended April 30, 2025. Revenue this quarter included: service revenue of $122.9 million, custodial revenue of $174.3 million, and interchange revenue of $57.4 million.

Net income was $69.4 million, or $0.82 per diluted share, for the first quarter ended April 30, 2026, compared to $53.9 million, or $0.61 per diluted share, for the first quarter ended April 30, 2025. Net income margin was 20% for the first quarter ended April 30, 2026, compared to 16% for the first quarter ended April 30, 2025.

Non-GAAP net income was $105.1 million, or $1.24 per diluted share, for the first quarter ended April 30, 2026, compared to $85.8 million, or $0.97 per diluted share, for the first quarter ended April 30, 2025.

Adjusted EBITDA was $164.5 million for the first quarter ended April 30, 2026, an increase of 17% compared to the first quarter ended April 30, 2025. Adjusted EBITDA was 46% of revenue, compared to 42% for the first quarter ended April 30, 2025.

Account and asset metrics

HSAs as of April 30, 2026 were 10.6 million, an increase of 8% year over year, including 909,000 HSAs with investments, an increase of 18% year over year. Total Accounts as of April 30, 2026 were 17.8 million, including 7.2 million complementary CDBs.

Total HSA Assets as of April 30, 2026 were $37.1 billion, an increase of 19% year over year. Total HSA Assets included $17.5 billion of HSA cash and $19.6 billion of HSA investments. Client-held funds, which are deposits held on behalf of our Clients to facilitate administration of our CDBs, and from which we generate custodial revenue, were $1.0 billion as of April 30, 2026.

Stock repurchase program

The Company repurchased 1.5 million shares of its common stock for $123.0 million during the first quarter ended April 30, 2026. In May 2026, the Company’s board of directors authorized an additional $1.0 billion of common stock repurchases under the program.

Business outlook

For the fiscal year ending January 31, 2027, management expects revenues of $1.410 billion to $1.420 billion. Its outlook for net income is between $242 million and $248 million, resulting in net income of $2.88 to $2.95 per diluted share. Its outlook for non-GAAP net income, calculated using the method described below, is between $392 million and $398 million, resulting in non-GAAP net income per diluted share of $4.66 to $4.73 (based on an estimated 84 million diluted weighted-average shares outstanding). Management expects Adjusted EBITDA of $625 million to $633 million.

See “Non-GAAP financial information” below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.

Conference call

HealthEquity management will host a conference call at 4:30 pm (Eastern Time) on Thursday, May 28, 2026 to discuss the fiscal 2027 first quarter financial results. The conference call will be accessible by dialing 1-833-630-1956, or 1-412-317-1837 for international callers, and referencing conference ID “HealthEquity.” A live audio webcast of the call will be available on the investor relations section of our website at http://ir.healthequity.com.

Non-GAAP financial information

To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.

  • Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
  • Non-GAAP net income is calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
  • Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.

Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP financial measures, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.

About HealthEquity

HealthEquity and its subsidiaries administer HSAs and other consumer-directed benefits for more than 17 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to save and improve lives by empowering healthcare consumers. For more information, visit www.healthequity.com.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, acquisition synergies, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “aims,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.

Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:

  • our ability to adequately place and safeguard our custodial assets, or the failure of any of our depository or insurance company partners;
  • our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;
  • our dependence on the continued availability and benefits of tax-advantaged HSAs and other CDBs;
  • the impact of fraudulent account activity involving our member accounts or our third-party service providers on our reputation and financial results;
  • our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;
  • the significant competition we face and may face in the future, including from those with greater resources than us;
  • our reliance on the availability and performance of our technology and communications systems;
  • potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;
  • the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;
  • our ability to comply with current and future privacy, healthcare, tax, ERISA, investment adviser and other laws applicable to our business;
  • our reliance on partners and third-party vendors for distribution and important services;
  • our ability to develop and implement updated features for our technology platforms and communications systems; and
  • our reliance on our management team and key team members.

For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the fiscal year ended January 31, 2026 and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact

Richard Putnam
801-727-1000
[email protected]

 
HealthEquity, Inc. and subsidiaries

Condensed consolidated balance sheets
(in thousands, except par value) April 30, 2026


    January 31, 2026


 
  (unaudited)      
Assets      
Current assets      
Cash and cash equivalents $ 265,369     $ 318,927  
Accounts receivable, net of allowance for doubtful accounts of $953 and $924 as of April 30, 2026 and January 31, 2026, respectively   122,003       123,696  
Prepaid expenses and other current assets   79,156       69,658  
Total current assets   466,528       512,281  
Property and equipment, net   3,800       3,177  
Operating lease right-of-use assets   34,578       36,310  
Intangible assets, net   1,073,045       1,097,172  
Goodwill   1,648,145       1,648,145  
Other assets   80,090       83,247  
Total assets $ 3,306,186     $ 3,380,332  
Liabilities and stockholders’ equity      
Current liabilities      
Accounts payable $ 14,219     $ 12,159  
Accrued compensation   26,664       60,392  
Accrued liabilities   84,941       74,388  
Operating lease liabilities   9,916       9,911  
Total current liabilities   135,740       156,850  
Long-term liabilities      
Long-term debt, net of issuance costs   942,656       957,379  
Operating lease liabilities, non-current   32,110       34,190  
Other long-term liabilities   52,932       31,007  
Deferred tax liability   95,353       93,710  
Total long-term liabilities   1,123,051       1,116,286  
Total liabilities   1,258,791       1,273,136  
Commitments and contingencies      
Stockholders’ equity      
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of April 30, 2026 and January 31, 2026, respectively          
Common stock, $0.0001 par value, 900,000 shares authorized, 83,927 and 85,007 shares issued and outstanding as of April 30, 2026 and January 31, 2026, respectively   8       8  
Additional paid-in capital   1,901,935       1,916,989  
Accumulated earnings   177,204       195,906  
Accumulated other comprehensive loss   (31,752 )     (5,707 )
Total stockholders’ equity   2,047,395       2,107,196  
Total liabilities and stockholders’ equity $ 3,306,186     $ 3,380,332  
               

   
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of operations (unaudited)
  Three months ended April 30,


 
(in thousands, except per share data)   2026       2025  
Revenue      
Service revenue $ 122,932     $ 119,784  
Custodial revenue   174,334       156,455  
Interchange revenue   57,375       54,605  
Total revenue   354,641       330,844  
Cost of revenue      
Service costs   78,326       88,005  
Custodial costs   11,655       10,747  
Interchange costs   8,348       7,781  
Total cost of revenue   98,329       106,533  
Gross profit   256,312       224,311  
Operating expenses      
Sales and marketing   26,833       25,984  
Technology and development   67,767       61,436  
General and administrative   31,131       25,536  
Amortization of acquired intangible assets   26,515       27,002  
Merger integration   1,113       1,275  
Total operating expenses   153,359       141,233  
Income from operations   102,953       83,078  
Other expense      
Interest expense   (12,588 )     (14,858 )
Other income, net   2,048       2,733  
Total other expense   (10,540 )     (12,125 )
Income before income taxes   92,413       70,953  
Income tax provision   22,995       17,038  
Net income $ 69,418     $ 53,915  
Net income per share:      
Basic $ 0.82     $ 0.62  
Diluted $ 0.82     $ 0.61  
Weighted-average number of shares used in computing net income per share:      
Basic   84,413       86,655  
Diluted   85,006       88,415  
               

 
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of comprehensive income (unaudited)
  Three months ended April 30,


 
(in thousands, except per share data)   2026       2025  
Net income $ 69,418     $ 53,915  
Other comprehensive loss        
Cash flow hedges        
Net unrealized losses   (25,897 )      
Reclassification of net gains included in net income   (148 )      
Net change, net of income tax benefit of $8,463 for the three months ended April 30, 2026   (26,045 )      
Total other comprehensive loss   (26,045 )      
Comprehensive income $ 43,373     $ 53,915  
               

 
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited)
  Three months ended April 30,


 
(in thousands)   2026       2025  
Cash flows from operating activities:      
Net income $ 69,418     $ 53,915  
Adjustments to reconcile net income to net cash provided by operating activities:      
Depreciation and amortization   38,214       38,741  
Stock-based compensation   19,406       14,336  
Amortization of debt discount and issuance costs   277       265  
Amortization of gains on derivatives   (196 )      
Deferred taxes   10,106       1,324  
Changes in operating assets and liabilities:      
Accounts receivable, net   1,693       1,750  
Prepaid expenses and other current and non-current assets   (11,690 )     (5,702 )
Operating lease right-of-use assets   1,732       1,649  
Accrued compensation   (31,242 )     (42,210 )
Accounts payable, accrued liabilities, and other current liabilities   (873 )     3,422  
Operating lease liabilities, non-current   (2,080 )     (1,968 )
Other long-term liabilities   2,761       (784 )
Net cash provided by operating activities   97,526       64,738  
Cash flows from investing activities:      
Purchases of software and capitalized software development costs   (15,930 )     (16,057 )
Purchases of property and equipment   (362 )     (86 )
Settlement of derivatives, net   2,388        
Net cash used in investing activities   (13,904 )     (16,143 )
Cash flows from financing activities:      
Repurchases of common stock   (123,314 )     (59,065 )
Principal payments on long-term debt   (15,000 )      
Settlement of client-held funds obligation, net   716       1,451  
Proceeds from exercise of common stock options   418       965  
Net cash used in financing activities   (137,180 )     (56,649 )
Decrease in cash and cash equivalents   (53,558 )     (8,054 )
Beginning cash and cash equivalents   318,927       295,948  
Ending cash and cash equivalents $ 265,369     $ 287,894  
               

 
HealthEquity, Inc. and subsidiaries
Condensed consolidated statements of cash flows (unaudited) (continued)
  Three months ended April 30,


 
(in thousands)   2026       2025  
Supplemental cash flow data:      
Interest expense paid in cash $ 18,512     $ 20,809  
Income tax refunds, net   (451 )     (46 )
Supplemental disclosures of non-cash investing and financing activities:      
Purchases of software and capitalized software development costs included in accounts payable, accrued liabilities, or accrued compensation   2,001       2,774  
Purchases of property and equipment included in accounts payable or accrued liabilities   765       546  
Repurchases of common stock included in accrued liabilities   2,858       2,000  
               



 
Stock-based compensation expense (unaudited)
Total stock-based compensation expense included in the condensed consolidated statements of operations and comprehensive income is as follows:
  Three months ended April 30,  
(in thousands)   2026       2025  
Cost of revenue $ 2,787     $ 3,387  
Sales and marketing   4,524       4,870  
Technology and development   3,953       5,920  
General and administrative   8,142       159  
Total stock-based compensation expense $ 19,406     $ 14,336  
               

 
Total Accounts (unaudited)
(in thousands, except percentages) April 30, 2026     April 30, 2025     % Change     January 31, 2026  
HSAs 10,635     9,886     8 %   10,570  
New HSAs from sales – Quarter-to-date 172     150     15 %   553  
New HSAs from sales – Year-to-date 172     150     15 %   1,040  
New HSAs from acquisitions – Year-to-date           *    
HSAs with investments 909     770     18 %   832  
CDBs 7,150     7,174     0 %   7,221  
Total Accounts 17,785     17,060     4 %   17,791  
Average Total Accounts – Quarter-to-date 17,834     17,122     4 %   17,462  
Average Total Accounts – Year-to-date 17,834     17,122     4 %   17,220  
*  Not meaningful
 

 
HSA Assets (unaudited)
(in millions, except percentages) April 30, 2026     April 30, 2025     % Change     January 31, 2026  
HSA cash $ 17,494     $ 17,066     3 %   $ 17,982  
HSA investments   19,613       14,205     38 %     18,482  
Total HSA Assets   37,107       31,271     19 %     36,464  
Average daily HSA cash – Quarter-to-date   17,706       17,281     2 %     17,090  
Average daily HSA cash – Year-to-date   17,706       17,281     2 %     17,082  
                             



 
HSA cash maturity schedule
The following table summarizes the amount of HSA cash held by our depository partners and insurance company partners that is expected to reprice by fiscal year and the respective average annualized yield currently earned on that HSA cash as of April 30, 2026:
Year ending January 31, (in billions, except percentages) HSA cash expected to reprice     Average annualized yield  
Remainder of 2027 $ 3.2     1.8 %
2028   2.4     3.9 %
2029   1.7     3.5 %
2030   2.0     4.3 %
Thereafter   7.2     4.0 %
Total (1) $ 16.5     3.6 %
(1)  Excludes $1.0 billion of HSA cash held in floating-rate contracts as of April 30, 2026.
 

 
Client-held funds (unaudited)
(in millions, except percentages) April 30, 2026     April 30, 2025     % Change     January 31, 2026  
Client-held funds $ 1,013     $ 925     10 %   $ 1,090  
Average daily Client-held funds – Quarter-to-date   1,036       902     15 %     879  
Average daily Client-held funds – Year-to-date   1,036       902     15 %     864  
                             

 
Reconciliation of net income to Adjusted EBITDA (unaudited)
  Three months ended April 30,


 
(in thousands)   2026       2025  
Net income $ 69,418     $ 53,915  
Interest income   (1,887 )     (2,733 )
Interest expense   12,588       14,858  
Income tax provision   22,995       17,038  
Depreciation and amortization   11,699       11,739  
Amortization of acquired intangible assets   26,515       27,002  
Stock-based compensation expense   19,406       14,336  
Merger integration expenses   1,113       1,275  
Amortization of incremental costs to obtain a contract   2,116       1,926  
Costs associated with unused office space   686       852  
Other   (161 )      
Adjusted EBITDA $ 164,488     $ 140,208  
               

 
Net income and Adjusted EBITDA as a percentage of revenue (unaudited)
  Three months ended April 30,


           
(in thousands, except percentages)   2026       2025     $ Change     % Change  
Net income $ 69,418     $ 53,915     $ 15,503     29 %
As a percentage of revenue   20 %     16 %          
Adjusted EBITDA $ 164,488     $ 140,208     $ 24,280     17 %
As a percentage of revenue   46 %     42 %          
                         

 
Reconciliation of net income outlook to Adjusted EBITDA outlook (unaudited)
  Outlook for the year ending  
(in millions) January 31, 2027  
Net income $242 – 248  
Interest income (6 )
Interest expense 50  
Income tax provision 81 – 83  
Depreciation and amortization 50  
Amortization of acquired intangible assets 104  
Stock-based compensation expense 87  
Merger integration expenses 6  
Amortization of incremental costs to obtain a contract 9  
Costs associated with unused office space 3  
Adjusted EBITDA $625 – 633  
Note: Values presented may not calculate due to rounding.  
   

 
Reconciliation of net income to non-GAAP net income (unaudited)
  Three months ended April 30,  
(in thousands, except per share data)   2026       2025  
Net income $ 69,418     $ 53,915  
Income tax provision   22,995       17,038  
Income before income taxes – GAAP   92,413       70,953  
Non-GAAP adjustments:          
Amortization of acquired intangible assets   26,515       27,002  
Stock-based compensation expense   19,406       14,336  
Merger integration expenses   1,113       1,275  
Costs associated with unused office space   686       852  
Total adjustments to income before income taxes – GAAP   47,720       43,465  
Income before income taxes – Non-GAAP   140,133       114,418  
Income tax provision – Non-GAAP (1)   35,034       28,604  
Non-GAAP net income   105,099       85,814  
           
Diluted weighted-average shares   85,006       88,415  
GAAP net income per diluted share $ 0.82     $ 0.61  
Non-GAAP net income per diluted share $ 1.24     $ 0.97  

(1)   The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.
     

 
Reconciliation of net income outlook to non-GAAP net income outlook (unaudited)
  Outlook for the year ending  
(in millions, except per share data) January 31, 2027  
Net income $242 – 248  
Income tax provision 81 – 83  
Income before income taxes – GAAP 322 – 330  
Non-GAAP adjustments:    
Amortization of acquired intangible assets 104  
Stock-based compensation expense 87  
Merger integration expenses 6  
Costs associated with unused office space 3  
Total adjustments to income before income taxes – GAAP 200  
Income before income taxes – Non-GAAP 522 – 530  
Income tax provision – Non-GAAP (1) 131 – 133  
Non-GAAP net income $392 – 398  
     
Diluted weighted-average shares 84  
GAAP net income per diluted share $2.88 – 2.95  
Non-GAAP net income per diluted share $4.66 – 4.73  
Note: Values presented may not calculate due to rounding.

(1)   The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occurring that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.
     

 
Certain terms
Term   Definition
HSA   Health Savings Account, which is a financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis.
CDB   Consumer-directed benefits offered by employers, including flexible spending and health reimbursement arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits.
HSA member   Consumers with HSAs that we serve.
Total HSA Assets   HSA members’ custodial cash assets held by our federally insured depository partners and our insurance company partners. Total HSA Assets also includes HSA members’ investments held by our custodial investment fund partner.
Client   Our employer clients.
Total Accounts   The sum of HSAs and CDBs on our platforms.
Client-held funds   Deposits held on behalf of our Clients to facilitate administration of our CDBs.
Network Partner   Our health plan partners, benefits administrators, and retirement plan recordkeepers.
Adjusted EBITDA   Earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, amortization of incremental costs to obtain a contract, costs associated with unused office space, and certain other non-operating items.
Non-GAAP net income   Calculated by adding back to GAAP net income before income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration expenses, acquisition costs, gains and losses on equity securities, costs associated with unused office space, and losses on extinguishment of debt, and subtracting a non-GAAP tax provision using a normalized non-GAAP tax rate.
Non-GAAP net income per diluted share   Calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.